EXCLUSIVE: Adial Pharmaceuticals Tells Benzinga 'Patient dosing in the second cohort has commenced following the successful completion of the first cohort'
Portfolio Pulse from Benzinga Newsdesk
Adial Pharmaceuticals has commenced patient dosing in the second cohort following the successful completion of the first cohort.
July 23, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Adial Pharmaceuticals has started dosing patients in the second cohort after successfully completing the first cohort, indicating progress in their clinical trials.
The commencement of patient dosing in the second cohort following the successful completion of the first cohort is a positive indicator of progress in Adial Pharmaceuticals' clinical trials. This development is likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100